Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on February 25, 2008, reporting events occurring on February 19, 2008. The company is a Delaware corporation focused on stem cell products.
Key Financial Metrics and Transactions
The filing details a private placement financing and a strategic partnership rather than periodic financial performance metrics.
- Capital Raised: $2,500,000 from the sale of common stock.
- Shares Issued: 615,309 shares.
- Price Per Share: $4.063.
- Investor: CJ CheilJedang Corporation ("CJ").
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, debt, or liquidity positions.
Material Changes and Agreements
On February 19, 2008, Neuralstem entered into two material agreements with CJ:
- Exclusive Option Agreement: CJ received an option to negotiate an exclusive license to develop, manufacture, market, and sell Neuralstem's stem cell products upon the successful completion of Neuralstem's first human clinical trial.
- Geographic Scope: The exclusive markets include Korea, Indonesia, Philippines, Malaysia, Singapore, and Vietnam, with a first right of negotiation for China and Japan.
- Registration Rights: CJ was granted demand and piggyback registration rights, requiring Neuralstem to include the shares in a registration statement within 90 days of closing or face a demand filing right on the 91st day.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, management commentary on financial outlook, or a detailed risk factor analysis beyond the standard incorporation of exhibits. The primary contingency noted is that the exclusive license option is contingent upon the successful completion of the company's first human clinical trial.
Key Facts for Investor Verification
- Verify the discrepancy between the requested company name (Palisade Bio) and the actual registrant (Neuralstem, Inc.).
- Confirm the status of Neuralstem's first human clinical trial, as this triggers the option for CJ to negotiate an exclusive license.
- Review the attached Exhibits 10.18, 10.19, and 10.20 for full terms of the Option, Securities Purchase, and Registration Rights Agreements.
- Check subsequent filings to confirm if the registration statement for the 615,309 shares was filed within the required 90-day window.